The use of radiopharmaceuticals for the non-invasive diagnosis of cancer has been
established in diagnostic radiology over the last few decades. In particular, with the use of …

Most cancer therapeutics (chemo, radiation, antibody-based, anti-angiogenic) are at best
partially and/or temporarily effective. In general, the causes for failure can be summarized …

This is the first time detailed and updated information on the targeted delivery of imaging
agents has been collected into a single handbook. This comprehensive volume presents the …

Simple Summary New clinical radiology scans using trace amounts of therapeutic cancer
drugs labeled with radioisotope injected into patients can provide oncologists with …

There is an increasing realization of the role of non-invasive monitoring of drug
pharmacology. In this review, we discuss the role of positron emission tomography in such …

Positron emission tomography (PET) allows three-dimensional quantitative determination of
the distribution of radioactivity permitting measurement of physiological, biochemical, and …

During the past 3 decades various chemotherapeutics have been directly or indirectly
radiolabeled for single photon emission computed tomography (SPECT) and positron …

Radiotherapy and radiology have been indispensable components in cancer care for many
years. The detection limit of small tumor foci as well as the development of radio-resistance …

Positron Emission Tomography (PET) has the potential to improve efficacy of established
and novel cancer therapies and to assist more rapid and rational progression of promising …

The recent developments of nuclear medicine in oncology have involved numerous
investigations of novel specific tumor-targeting radiopharmaceuticals as a major area of …